Serum levels of interleukin-6 in contacts of active pulmonary tuberculosis

Fernando Henrique Azevedo Lopes; Lívia Coelho de Assis; Roberto da Justa Pires Neto; Karine Paschoal Botelho; Kêlia Miranda Sá; Cristiane Cunha Frota; José Walter Correia; Max Victor Carioca Freitas

ABSTRACT

Introduction: It is estimated that over two billion individuals are infected by Mycobacterium tuberculosis worldwide. Interleukin-6 (IL-6) is an important cytokine whose serum levels are commonly high in active pulmonary tuberculosis (TB). IL-6 screening in contacts of patients with TB may be useful to monitor the progress of the infectious process and to infer the risk of progression to active disease.

Objective: To evaluate the serum levels of interleukin-6 in contacts of patients with active pulmonary tuberculosis and to compare them with two other groups: a) patients affected by active pulmonary tuberculosis; b) non-contacts of tuberculosis.

Methods: Cross-sectional study with 15 contacts of patients with active pulmonary tuberculosis, selected according to the protocol recommended by the Ministry of Health. The serum levels of interleukin-6 were measured by Enzyme-linked immunosorbent assay (ELISA). The same test was also applied in the two comparison groups: 38 patients with active pulmonary tuberculosis (confirmed by clinical examination, X-rays of the chest and bacilloscopy) and 63 non-contacts (healthy blood donors).

Results: In the contact group, the median IL-6 concentration was 1.7 pg/ml (0.96-4.8 pg/ml). For those affected by active pulmonary tuberculosis and non-contact individuals, these values corresponded to 4.3 pg/ml (0.5-24 pg/ml) and 0.5 pg/ml (0-2.8 pg/ml), respectively ($p < 0.0001$). Conclusion: Contacts of patients with active pulmonary tuberculosis had significantly higher IL-6 serum levels (3.4 times higher) in relation to non-contact individuals, but on a lower level (2.5 times lower) when compared to those affected by active disease.

Key words: Mycobacterium tuberculosis; latent tuberculosis; tuberculosis; interleukin-6; enzyme-linked immunosorbent assay.

INTRODUCTION

Tuberculosis remains a major challenge to public health worldwide. It is estimated that one out of every three humans is infected with its etiologic agent, *Mycobacterium tuberculosis* (*M. tuberculosis*). Although there have been effective drugs for over 50 years, every 15 seconds someone dies of tuberculosis worldwide, and each second there is a new case of infection by *M. tuberculosis*. Epidemiological data show that in 2010, the incidence rate of TB in Ceará was 43 cases per 100,000 inhabitants, which was higher than the national average, accounting for 37.7 cases per 100,000 inhabitants in the same year.

Although there are numerous studies in the scientific literature about the immunopathogenesis of tuberculosis in its active form, there are few investigations focusing on the latent *M. tuberculosis* infection.
(LTBI). This condition is asymptomatic, non-transmissible, and presupposes the absence of clinical or radiological evidence of the disease, although there are viable bacilli in the tissues. This scarcity of studies may be partly due to the difficulty in identifying LTBI accurately and unequivocally. To date, the diagnostic approach has been based on positive tuberculin test (TT) or interferon-gamma release assays (IGRAs)\(^{11, 18}\). These methods, however, are unable to distinguish latent infection from active disease, inasmuch as they only indicate an immunologic sensitization due to prior exposure to M. \textit{tb} antigens. Both are inaccurate in confirming the presence of viable bacilli\(^{12, 22}\).

Tuberculosis control lies in early identification and prophylactic treatment of healthy individuals infected with M. \textit{tb} who are at imminent risk of progression to active disease\(^{12}\).

In most individuals infected with M. \textit{tb}, the immune system is able to maintain the bacillus under control, although it does not eliminate it altogether. Among individuals exposed to M. \textit{tb} and those who developed an adaptive immune response to it, hence considered affected by LTBI, only a small proportion (about 5\%) will evolve into the active form of the disease within 2-5 years. 95\% will remain free of the active disease unless they become immunocompromised, namely in the case of coinfection with human immunodeficiency virus (HIV) or undergoing immunosuppressive treatment\(^{5}\).

The control of M. \textit{tb} by the immune system is founded on a typical cellular response that is triggered in most individuals by the hypersensitivity reaction mediated by T\(_n\)\(_1\) lymphocytes within 2-10 weeks after infection\(^\text{8, 9, 22}\). This reaction depends on the integrated action of several cytokines such as interleukin-12 (IL-12), IFN-\(\lambda\), tumor necrosis factor alpha (TNF-\(\alpha\)) as well as reactive nitrogen and oxygen intermediates. The combined actions of these substances promote the destruction of bacilli previously phagocytosed by infected macrophages\(^\text{5, 7, 9, 13}\).

Interleukin-6 (IL-6) has been noted for having a relevant role in the immunopathogenesis of tuberculosis. For instance, it is known for stimulating the secretion of IFN-gamma, a crucial cytokine in the activation of macrophages infected with M. \textit{tb}, although the precise mechanism of such interaction still requires further clarification\(^{10, 19}\).

### OBJEKTIVE

The present study had the objective to determine IL-6 blood levels in contacts of patients with active pulmonary tuberculosis and compare them with non-contact individuals as well as patients with the active disease.

### METHODS

#### Research subjects

The test group comprised 15 contacts of patients with active pulmonary tuberculosis, who aged between 15 and 81 years and were diagnosed through clinical examination, radiography and pulmonary smear. They were admitted at Hospital São José de Doenças Infecciosas (HSJ) and at Centro de Saúde de Família Anastácio Magalhães (CSFAM) in Fortaleza, Ceará, Brazil. The definitions of contact and LTBI adopted herein were those recommended by the Ministry of Health (MH)\(^{14}\). Thus, asymptomatic individuals who lived with the index case at the time of diagnosis of active pulmonary tuberculosis were considered contacts. This interaction could occur at home and/or work environments, long-stay institutions, school and kindergarten. In accordance with MH, contacts that presented TT \(\geq 5\) mm and a normal chest x-ray were considered LTBI. When TT result was \(< 5\) mm, subjects were advised to return after eight weeks in order to repeat the test. Thus, those who presented TT alterations were also considered LTBI. An increase of at least 10 mm in induration in comparison with the previous TT was regarded as conversion.

One hundred and one subjects who had participated in a previous study carried out by the same research group were also included in the present investigation\(^{2}\), which was stratified into two subgroups:

1) healthy non-contacts - 63 voluntary blood donors from the Center for Hematology and Hemotherapy of Ceará, Brazil (Hemoce), with no previous reports of tuberculosis or contact with patients with tuberculosis, according to data collected from a questionnaire; 2) thirty-eight patients with active pulmonary tuberculosis (TB group) confirmed by positive sputum culture, coming from Hospital de Messejana, Hospital de Maracanaú and Hospital Geral Dr. César Cals, Fortaleza, Ceará, Brazil.

#### Determination of IL-6

The serum concentrations of IL-6 in peripheral venous blood were assessed by an enzyme immunoassay (ELISA), according to guidelines provided by Invitrogen Corporation (Frederick - Maryland, USA), which supplied the kit.

#### Statistical Analysis

The Mann-Whitney and Kruskal-Wallis tests were used to compare IL-6 serum concentrations. The Shapiro-Wilkinson test was applied to assess the normality of the assessed samples. The level of statistical significance was set to \(p\) values lower than 0.05.
Ethical considerations

This study was approved by the Ethical Research Committees (Comitê de Ética em Pesquisa [CEP]) from the University Hospital Walter Cantídio (Protocol 125.12.10) and HSJ (Protocol 032/2011). All study subjects signed an Informed Consent Form (ICF). Both ERCs agreed that the project was in accordance with resolution 196/96 of the National Health Council (CNS), which regulates research involving human subjects in Brazil.

RESULTS

Demographic data

The demographic characteristics of the contact groups and of both comparison groups are shown in Table.

<table>
<thead>
<tr>
<th>TABLE – Demographic characteristics of contacts of patients with active pulmonary tuberculosis and non-contacts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic characteristics</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td>Female</td>
</tr>
<tr>
<td>Median age (min-max)</td>
</tr>
</tbody>
</table>

IL-6 concentrations

The median of IL-6 serum levels was 1.7 pg/ml (0.96 to 4.8 pg/ml) in the test group (contacts). As to the comparison groups, the median IL-6 concentration levels were 4.3 pg/ml (0.5-24 pg/ml) and 0.5 pg/ml (0 to 2.8 pg/ml) for TB subgroups and non-contacts, respectively. There was statistical significance (p < 0.0001) when the three groups were contrasted. These data are shown in Figure.

DISCUSSION

IL-6 is a pleiotropic cytokine that performs several pathophysiological functions in humans(17). Produced by a variety of cells such as mononuclear phagocytes, fibroblasts, endothelial cells, T and B lymphocytes, among others, IL-6 plays a major role in stimulating the synthesis of acute-phase proteins, mainly C-reactive protein, in response to various stimuli(15).

In active pulmonary tuberculosis, the present investigation demonstrated that blood levels of IL-6 were significantly higher in patients (8.6 times) in contrast with healthy controls(12).

Nevertheless, the exact role of this cytokine in tuberculosis has proved to be controversial.

IL-6 secreted by macrophages infected with M. tuberculosis is able to inhibit the response to IFN-α by non-infected macrophages adjacent to infected ones(16). These results reveal that IL-6 may be involved in the inability of the cellular immune response to eradicate the infection. This cytokine can also be harmful to mycobacterial infections, insofar as it is able to inhibit the production of TNF-α and interleukin-1 beta (IL-1β)(20). It is possible that high concentrations of IL-6, as observed in active pulmonary TB, may contribute to the disease progression, whereas intermediate concentrations found in contacts could contribute to the maintenance of the latent state.

On the other hand, there are studies that suggest that IL-6 has a protective role in relation to M. tuberculosis. Murines with deficiency in IL-6 production are more susceptible to infection by M. tuberculosis. Furthermore, IL-6 gene knockout mice have lower IFN-α production, which plays a crucial role in the protective response to M. tuberculosis(21). Thus, according to the data obtained herein, it can be concluded that IL-6 serum levels in contact group were insufficient to promote the neutralization of cytokines (particularly TNF-α), which are involved in the formation or development of granuloma.

IL-6 serum levels were measured and compared in the three analyzed groups. For the contacts, the concentration was 3.4 times...
investigated IL-6 serum levels in contacts of patients with active pulmonary tuberculosis.

**CONCLUSION**

The present study demonstrates that the production of IL-6 is higher in both groups: patients with TB and contacts of active pulmonary TB. Moreover, its production is exacerbated in the first group. Furthermore, non-contact individuals, hence with no antigenic challenge by *M. tb*, produced significantly lower amounts of IL-6. Future studies are required to confirm these data and their potential clinical applications.

**FUNDING**

Development Coordination of Higher Education Personnel (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior [CAPES]).

**REFERENCES**